Updated 12 sec ago · auto-refreshing
Trending claims
The fastest-moving factual assertions across the open web, ranked by velocity and weighted by credibility.
In her book 'Mindset', Dr. Carol S. Dweck, a psychologist at Stanford, contrasts a fixed mind-set with a growth mind-set.
Paul Losoff is a clinical psychologist in Northbrook, Illinois.
Ashley Chin is a clinical psychologist in Gainesville, Florida.
The book 'Right Kind of Wrong' was published in 2023.
In her book 'Right Kind of Wrong', Dr. Amy Edmonson distinguishes between basic, complex, and intelligent failures.
Sandhya Krishnan is a postdoctoral research fellow at the University of Arkansas at Little Rock who has studied failure.
Amanda Cassil is a clinical psychologist in Pasadena, California.
Dr. Kristin Neff's book 'Self-Compassion', published in 2011, presents self-compassion as an alternative to self-esteem and includes exercises.
Dr. Lucas stated that in most cases, pancreatic cancer does not manifest before age 50, so testing before then is not usually recommended.
Dr. Anna Berkenblit of the Pancreatic Cancer Action Network stated that two recent developments have the potential to be game changers for pancreatic cancer.
The author's brother, Bill, had his funeral about two weeks after the author visited him.
The author's brother, Ron, is 71 years old.
The author's brother, Darrell, died about a week after the author visited him.
Dr. Lucas stated that subtle shifts like changes in blood glucose or unexplained weight loss can be clues to pancreatic disease two to three years before diagnosis.
The author's brother Bill, who died at 74, had served in the Navy for 30 years.
The author's brother Jim, who died at 77 and had Alzheimer's disease, chose to forgo treatment for his pancreatic cancer.
The author's brother Bill underwent surgery, radiation, and chemotherapy for pancreatic cancer.
A new treatment for high-risk pancreatic cancer patients with removed tumors involves a vaccine using mRNA technology.
Dr. Anna Berkenblit is the chief scientific and medical officer of the Pancreatic Cancer Action Network.
The drug daraxonrasib, recently approved by the FDA, doubled life expectancy to over 13 months for certain metastatic pancreatic cancer patients in a clinical trial, compared to under 7 months for those on chemotherapy.